A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies
- Conditions
- Relapsed or Refractory Hematologic Malignancies
- First Posted Date
- 2024-02-09
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 74
- Registration Number
- NCT06252298
- Locations
- 🇨🇳
Beijing Chaoyang Hospital ,Capital Medical University, Beijing, Beijing, China
Efficacy and Safety of SCT650C in Participants With Axial Spondyloarthritis
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 168
- Registration Number
- NCT06197009
- Locations
- 🇹🇷
Hacettepe University Faculty of Medicine, Ankara, Hacettepe Mh., Turkey
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years
- Conditions
- HPV InfectioNHPV-Related Carcinoma
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 18000
- Registration Number
- NCT06041061
- Locations
- 🇨🇳
Guangxi Center for Disease Control and Prevention, Nanning, Guangxi, China
🇨🇳Henan Center for Disease Control and Prevention, Zhengzhou, Henan, China
🇨🇳Shanxi Center for Disease Control and Prevention, Taiyuan, Shanxi, China
A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines
- Conditions
- COVID-19SARS-CoV-2 Infection
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 600
- Registration Number
- NCT05933512
Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05894707
- Locations
- 🇦🇺
Linear Clinical Research - Joonadalup, Joondalup, Western Australia, Australia
🇦🇺Linear Clinical Research - B Block, Nedlands, Western Australia, Australia
🇦🇺Linear Clinical Research - Harry Perkins, Nedlands, Western Australia, Australia
Study on the Antibody Level Against SARS-CoV-2 （COVID-19）in Dazhu County in 2023
- Conditions
- COVID-19
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 20000
- Registration Number
- NCT05758675
- Locations
- 🇨🇳
Dazhu County Center for Disease Control and Prevention, Dazhou, Sichuan, China
A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People
- Conditions
- COVID-19 SARS-CoV-2 Infection
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 6000
- Registration Number
- NCT05683561
A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine
- Conditions
- COVID-19 Pandemic
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 518
- Registration Number
- NCT05652543
- Locations
- 🇨🇳
Lianshui County Center for Disease Control and Prevention, Lianshui, Jiangsu, China
🇨🇳Jiangsu Center for Disease Control and Prevention, Nanjing, Jiangsu, China
🇨🇳Taizhou Vaccine Clinical Research Center, Taizhou, Jiangsu, China
SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck Squamous Carcinoma
- Interventions
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05552807
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, China
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 Years
- Conditions
- COVID-19SARS-CoV-2 Infection
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT05522829